Recent corporate press releases from Foghorn Therapeutics highlight updates regarding its clinical oncology pipeline progress, quarterly financial results detailing robust cash runway metrics, and executive appointments. Additional disclosures focus on scientific presentations at major medical conferences showcasing data from its targeted gene-transcription programs.